Q-omics provides the consensus-scored CYB5R2 profile across patient tissues and cancer cell-line models. CYB5R2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CYB5R2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CYB5R2 protein abundance shows 18,239 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LGG, KIRC, and LUAD as cancer lineages where CYB5R2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB5R2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB5R2 survival associations across molecular data types. CYB5R2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB5R2 RNA expression–survival associations across cancer types. High CYB5R2 expression shows unfavorable associations in LGG, LAML and KIRP, but favorable associations in LUSC, OV and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CYB5R2 RNA expression.
This table summarizes CYB5R2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CYB5R2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB5R2 shows lower tumor expression in KIRC and higher tumor expression in BLCA, HNSC, LUSC, COAD and STAD. The KIRC box plot shows higher CYB5R2 RNA expression in normal versus tumor tissue (log2 FC = −0.703, t-test p < 0.001).
This table shows molecular features associated with CYB5R2 in patient tissues and cancer cell lines. In patient samples, CYB5R2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CYB5R2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
